NCT05984875Recruiting
The Immune Landscape of Epithelial Ovarian Cancer
The Immune Landscape of Epithelial Ovarian Cancer: a Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This is a single center prospective observational study to characterize the immune landscape of newly diagnosed epithelial ovarian cancer (OC). Patients with newly diagnosed epithelial OC will be enrolled in 4 different cohorts: A) Newly diagnosed high grade serous or endometroid OC undergoing primary debulking surgery; B) Newly diagnosed high grade serous or endometroid OC undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery; C) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing primary debulking surgery; D) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing NACT followed by interval debulking surgery. A cohort of women undergoing adnexectomy for benign pathology will be enrolled (cohort E) for comparative analysis. Enrolled patients will be asked to provide the following biological samples at specified time points: archival and fresh tumor tissue, peripheral blood samples, rectal and vaginal swabs, ascites (when present). The main aim of the study is to characterize the immune landscape of epithelial OC in tumor tissue and peripheral blood and correlate the presence of myeloid-derived suppressive cells (MDSCs) and other immune infiltrates and of the systemic immune response with progression free interval (PFI) in epithelial OC.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 74 (estimated)
- First submitted
- 24 Jul 2023
- Start date
- 20 Dec 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Oncology Institute of Southern Switzerland
- Diseases
- Ovarian cancer
- NCT number
- NCT05984875
What you commit to
- Study type: Observational
- Planned participants: 74
- From 20 Dec 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other active concomitant neoplasms that might confound the results of the planned analysis.
- Ongoing chronic treatment with steroids or other immune suppressive agents at the time of study entry
Other illness
- Ongoing active autoimmune disease requiring treatment or condition of immune deficiency
Who the study is looking for
- Suspicious diagnosis of epithelial ovarian cancer (subsequent histologically confirmation required)
- Plan to undergo a surgical procedure for the management of epithelial ovarian cancer or recurrent ovarian cancer previously treated with conventional treatment and involved in the trial as group A-D
- ≥18 years old
- ECOG Performance Status ≤ 2
- Written informed consent
- Indication for adnexectomy for a benign gynecological condition
- ≥18 years old
- ECOG Performance Status ≤ 2
- Written informed consent
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oncology Institute of Southern Switzerland Coordinator of this site? Confirm its status | Bellinzona | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.